Group items tagged

A newly licensed 1mg/ml Omeprazole Powder for Oral Suspension has been developed by Rosemont Pharmaceuticals to meet the special needs of babies from 1 to 12 months old who have gastro-oesophageal reflux disease (GORD). In infants, the symptoms of GORD can be particularly distressing for both the child and parent. Previously, Rosemont Omeprazole Powder for Oral Suspension has been available in 2mg/ml and 4mg/ml strengths. However, the addition of the new 1mg/ml product ensures that the needs of all patient groups with GORD are sufficiently met. The Rosemont range of Omeprazole Powder for Oral Suspension products are the only PPIs (proton pump inhibitors) indicated for use in babies from 1 month to 1 year. Symptoms of GORD in infants are usually resolved by 1 year of age1, so it is key that there is a licensed treatment option available for the 1 to 12 month patient group.

With more than half of the UK population experiencing gum problems and many not believing their condition warrants treatment, there is a significant need for an oral care range that promotes good gum health and prevents future issues. Corsodyl is set to launch a new Gum Strength & Protect line, featuring two toothpastes and a daily mouthwash which are clinically proven to protect against gum problems. This range aims to meet the growing consumer demand for oral care solutions that help proactively manage gum health and prevent issues related to poor oral hygiene. The Corsodyl Gum Strength & Protect line is designed to strengthen the gum seal around teeth, offering long-lasting protection. The product is enriched with hyaluronic acid, a key building block for strong gums, and includes IPMP (Isopropyl Methylphenol) and zinc as antibacterial active ingredients.